From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunoth...
| Publicado en: | Current Oncology Vol. 31; no. 2; pp. 778 - 801 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Feb2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175645107&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 175645107 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Feb2024 vid: 31 iid: 2 pid: 97109 pub: MDPI artinfo: ui: 175645107 10.3390/curroncol31020058 175645107 ppf: 778 ppct: 23 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. aug: au: Synoradzki, Kamil J. Paduszyńska, Natalia Solnik, Malgorzata Toro, Mario Damiano Bilmin, Krzysztof Bylina, Elżbieta Rutkowski, Piotr Yousef, Yacoub A. Bucolo, Claudio Zweifel, Sandrine Anne Reibaldi, Michele Fiedorowicz, Michal Czarnecka, Anna M. affil: Environmental Laboratory of Pharmacological and Toxicological Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Str., 02-106 Warsaw, Poland sug: ab: Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp—a T cell–redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells. Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach. Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|